von Redaktion LCGC | Juli 15, 2011
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W Journal: Cancer Research, Vol 71, No 14, July 2011, doi:...
von Redaktion LCGC | Juni 15, 2011
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Hammerman P, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T,...
von Redaktion LCGC | Juni 15, 2011
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines Scheffler M, Di Gion P, Doroshyenko O, Wof J, Fuhr U Journal: Clinical pharmacokinetics, Vol 50, No 6, June 2011. doi: 10.2165/11587020-000000000-00000Veröffentlichung: Juni...
von Redaktion LCGC | Mai 15, 2011
Blood-based gene expression signatures for early detection of lung cancer Zander T, Gaarz A, Staratschek-Jox A, Classen S, Henseler M, Debey-Pascher S, Eggle D, Ansen S, Massoudi N, Stecki M, Kraut M, Frommolt P, Hahn M, Beyer M, Thomas RK, Popov A, Mauch C, Delank...
von Redaktion LCGC | Mai 15, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimens Querings S, Altmüller J, Ansén S, Zander T, Seidel D, Gabler F, Peifer M, Markert E, Stemshorn K, Timmermann B, Saal B, Klose S, Ernestus K, Scheffler M, Engel-Riedel W, Stoelben E, Brambilla E,...
